Podcast Episodes

Back to Search
1.43 Andexanet Alfa with Dr. Tom Deloughery & National Medicaid Policy with Dr. John McConnell
1.43 Andexanet Alfa with Dr. Tom Deloughery & National Medicaid Policy with Dr. John McConnell

In this episode we discuss the controversy over the recent article in NEJM, "Full Study Report of Andexanet Alfa for Bleeding Associated with Factor …

7 years, 6 months ago

Short Long
View Episode
1.42 Caplacizumab for TTP with Dr. Sven Olson & Economics of Drug Pricing with Dr. Inma Hernández
1.42 Caplacizumab for TTP with Dr. Sven Olson & Economics of Drug Pricing with Dr. Inma Hernández

In the first half of this episode, Dr. Sven Olson of OHSU joins us to help critique the recent NEJM paper, "Caplacizumab Treatment for Acquired Throm…

7 years, 6 months ago

Short Long
View Episode
1.41 Geneva Oath and Financial Relationships Among Guideline Authors with Dr. Joshua Niforatos
1.41 Geneva Oath and Financial Relationships Among Guideline Authors with Dr. Joshua Niforatos

We feature two interviews this week: the first is a hallway conversation with [soon-to-be] Dr. Antonious Hazim of OHSU on the Declaration of Geneva a…

7 years, 7 months ago

Short Long
View Episode
1.40 The World of Hematology with Dr. Thomas Deloughery
1.40 The World of Hematology with Dr. Thomas Deloughery

This episode features an interview with hematologist Dr. Thomas Deloughery of OHSU. We cover a broad range of topics including 23andMe, wilderness me…

7 years, 7 months ago

Short Long
View Episode
1.39 Looking Back On a Tenure in Medicine with Dr. Alex Denes
1.39 Looking Back On a Tenure in Medicine with Dr. Alex Denes

In this episode we interview Dr. Alex Denes of OHSU on his decades-long career in medicine: what practices have changed and what have stayed the same…

7 years, 7 months ago

Short Long
View Episode
1.38 Lartruvo, New Directions for Cancer Trials, Gene Expression Profiling, & Dr. Miriam Knoll
1.38 Lartruvo, New Directions for Cancer Trials, Gene Expression Profiling, & Dr. Miriam Knoll

In this episode we tackle Eli Lilly's drug Lartruvo (olaratumab) and the under-powered phase II trial that led to its FDA accelerated approval; a vie…

7 years, 7 months ago

Short Long
View Episode
1.37 BONUS! Medical Reversal for a General Audience
1.37 BONUS! Medical Reversal for a General Audience

This BONUS episode is the recording of a talk given at the Salem City Club on January 11, 2019. It's the talk on medical reversal that has been featu…

7 years, 7 months ago

Short Long
View Episode
1.36 Generic Price Competition & Military Surgical Advances with Dr. Martin Schreiber
1.36 Generic Price Competition & Military Surgical Advances with Dr. Martin Schreiber

This week we dive into the recent paper by Drs. Cole and Dusetzina titled "Generic Price Competition For Specialty Drugs: Too Little, Too Late?". We …

7 years, 7 months ago

Short Long
View Episode
1.35 BONUS! Conflict of Interest in Oncology
1.35 BONUS! Conflict of Interest in Oncology

This BONUS episode is the recording of a lecture given to the Bioethics Study Group at OHSU on January 9, 2019 on conflict of interest, specifically …

7 years, 7 months ago

Short Long
View Episode
1.34 Endpoints in ECOG-ACRIN 2511, Update to KEYNOTE-024, & Mentorship with Dr. Joseph Shatzel
1.34 Endpoints in ECOG-ACRIN 2511, Update to KEYNOTE-024, & Mentorship with Dr. Joseph Shatzel

In this episode, we discuss two recent papers published in the Journal of Clinical Oncology: ECOG-ACRIN 2511 and the update adding overall-survival a…

7 years, 7 months ago

Short Long
View Episode

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us